<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35391498</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1520-6777</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>07</Day>
            </PubDate>
          </JournalIssue>
          <Title>Neurourology and urodynamics</Title>
          <ISOAbbreviation>Neurourol Urodyn</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Do medication prescription patterns follow guidelines in a cohort of women with interstitial cystitis/bladder pain syndrome?</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/nau.24923</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe prescription prevalence of oral bladder pain medications among women with interstitial cystitis/bladder pain syndrome (IC/BPS) and to compare with current treatment guidelines.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We sampled female patients with an ICD-9/10 diagnosis of IC/BPS (595.1/N30.10) by querying active users of the Veterans Health Administration. Medical records were reviewed to determine whether patients met IC/BPS diagnostic criteria. A cohort of women with other pelvic pain disorders was identified. Prescription prevalence of typical non-narcotic oral bladder pain medications was compared between the two groups and healthy controls. Prescription prevalence was also compared before and after the diagnosis of IC/BPS was made using Poisson regression.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 641 women who met criteria for IC/BPS and 197 women with "Other pelvic pain" disorders. Women with IC/BPS were prescribed a pain medication more often than those with "Other pelvic pain" (77% vs. 59%, p &lt; 0.0001). Of the women with IC/BPS, 44% tried three or more pain medications. Of women with a diagnosis of IC/BPS, only 67% were prescribed an American Urological Association-recommended medication. Prescription prevalence increased after diagnosis for both pentosan polysulfate (10%-29%, p &lt; 0.0001) and hydroxyzine (17%-40%, p &lt; 0.0001), but not for amitriptyline or cimetidine. Amitriptyline was prescribed to 223 women with IC/BPS, only 125 of which (56%) had a documented history of depression.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Many women with IC/BPS required multiple bladder prescriptions, highlighting the difficulty in finding an effective treatment for IC/BPS. Pentosan polysulfate and hydroxyzine were preferred IC/BPS medications. Our next step will be to analyze treatment patterns in those patients who did not receive medications.</AbstractText>
          <CopyrightInformation>© 2022 Wiley Periodicals LLC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tholemeier</LastName>
            <ForeName>Lauren N</ForeName>
            <Initials>LN</Initials>
            <Identifier Source="ORCID">0000-0003-3354-228X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bresee</LastName>
            <ForeName>Catherine</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Biostatistics Core at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Hoedt</LastName>
            <ForeName>Amanda M</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Durham Veterans Affairs Health System, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barbour</LastName>
            <ForeName>Kamil E</ForeName>
            <Initials>KE</Initials>
            <AffiliationInfo>
              <Affiliation>Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Jayoung</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Freedland</LastName>
            <ForeName>Stephen J</ForeName>
            <Initials>SJ</Initials>
            <Identifier Source="ORCID">0000-0002-8104-6419</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anger</LastName>
            <ForeName>Jennifer T</ForeName>
            <Initials>JT</Initials>
            <Identifier Source="ORCID">0000-0002-3897-5941</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Urology, UC San Diego Medical Center, La Jolla, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <Acronym>CC</Acronym>
            <Agency>CDC HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <Acronym>CC</Acronym>
            <Agency>CDC HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Neurourol Urodyn</MedlineTA>
        <NlmUniqueID>8303326</NlmUniqueID>
        <ISSNLinking>0733-2467</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">amitriptyline</Keyword>
        <Keyword MajorTopicYN="N">bladder pain syndrome</Keyword>
        <Keyword MajorTopicYN="N">hydroxyzine</Keyword>
        <Keyword MajorTopicYN="N">interstitial cystitis</Keyword>
        <Keyword MajorTopicYN="N">pentosan polysulfate</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>20</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35391498</ArticleId>
        <ArticleId IdType="doi">10.1002/nau.24923</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Berry SH, Elliott MN, Suttorp M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186(2):540-544. doi:10.1016/j.juro.2011.03.132</Citation>
        </Reference>
        <Reference>
          <Citation>Tung A, Hepp Z, Bansal A, Devine EB. Characterizing health care utilization, direct costs, and comorbidities associated with interstitial cystitis: a retrospective claims analysis. J Manag Care Spec Pharm. 2017;23(4):474-482. doi:10.18553/jmcp.2017.23.4.474</Citation>
        </Reference>
        <Reference>
          <Citation>Hanno PM, Burks DA, Clemens JQ, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185(6):2162-2170. doi:10.1016/j.juro.2011.03.064</Citation>
        </Reference>
        <Reference>
          <Citation>Hanno PM, Erickson D, Moldwin R, Faraday MM, American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193:1545-1553. doi:10.1016/j.juro.2015.01.086</Citation>
        </Reference>
        <Reference>
          <Citation>Cox A, Golda N, Nadeau G, et al. CUA guideline: diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Can Urol Assoc J. 2016;10(5-6):E136-E155. doi:10.5489/cuaj.3786</Citation>
        </Reference>
        <Reference>
          <Citation>Lusty A, Kavaler E, Zakariasen K, Tolls V, Nickel JC. Treatment effectiveness in interstitial cystitis/bladder pain syndrome: do patient perceptions align with efficacy-based guidelines? Can Urol Assoc J. 2018;12(1):E1-E5. doi:10.5489/cuaj.4505</Citation>
        </Reference>
        <Reference>
          <Citation>Sant GR, Propert KJ, Hanno PM, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003;170:810-815. doi:10.1097/01.ju.0000083020.06212.3d</Citation>
        </Reference>
        <Reference>
          <Citation>Theoharides TC, Sant GR. Hydroxyzine therapy for interstitial cystitis. Urology. 1997;49(5A Suppl):108-110. doi:10.1016/s0090-4295(97)00182-9</Citation>
        </Reference>
        <Reference>
          <Citation>Hill JR, Isom-Batz G, Panagopoulos G, Zakariasen K, Kavaler E. Patient perceived outcomes of treatments used for interstitial cystitis. Urology. 2008;71(1):62-66. doi:10.1016/j.urology.2007.09.011</Citation>
        </Reference>
        <Reference>
          <Citation>van Ophoven A, Vonde K, Koch W, Auerbach G, Maag KP. Efficacy of pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome: results of a systematic review of randomized controlled trials. Curr Med Res Opin. 2019;35(9):1495-1503. doi:10.1080/03007995.2019.1586401</Citation>
        </Reference>
        <Reference>
          <Citation>Imamura M, Scott NW, Wallace SA, et al. Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis. Cochrane Database Syst Rev. 2020;7(7):CD013325. doi:10.1002/14651858.CD013325.pub2</Citation>
        </Reference>
        <Reference>
          <Citation>Paredes Mogica JA, De EJB. Pentosan polysulfate maculopathy: what urologists should know in 2020. Urology. 2021;147:109-118. doi:10.1016/j.urology.2020.08.072</Citation>
        </Reference>
        <Reference>
          <Citation>Di X, Luo D, Jin X, Zhao W, Li H, Wang K. Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis. Int Urogynecol J. 2021;32(5):1129-1141. doi:10.1007/s00192-020-04659-w</Citation>
        </Reference>
        <Reference>
          <Citation>van Ophoven A, Hertle L. Long-term results of amitriptyline treatment for interstitial cystitis. J Urol. 2005;174(5):1837-1840. doi:10.1097/01.ju.0000176741.10094.e0</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
